Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Mechanism of action of bomedemstat

Harinder Gill • 16 Jun 2021
EHA 2021
Myelofibrosis Myeloproliferative Neoplasms Bomedemstat

Harinder Gill, MBBS, PDipID, MD, MRCP, FRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, outlines the mechanism of action of bomedemstat. Lysine-specific demethylase-1 (LSD1) is an enzyme crucial for malignant stem cells and differentiation. Bomedemstat, an orally active LSD1 inhibitor, blocks these actions, allowing progenitors to mature to megakaryocytes. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Harinder Gill

2:20
JAK inhibition in MF: monotherapy versus combination treatment
Harinder Gill • 11 Dec 2023
2:41
Bomedemstat combined with ruxolitinib for the treatment of MF: early results of a Phase II trial
Harinder Gill • 11 Dec 2023
2:05
Updated results of the AAA regimen in newly-diagnosed acute promyelocytic leukemia
Harinder Gill • 11 Dec 2023
3:10
Phase II study of all-oral AAA regimen for patients with newly diagnosed APL
Harinder Gill • 10 Jun 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals